Influence of genetic polymorphisms in glutathione-S-transferases gene in response to imatinib among Brazilian patients with chronic myeloid leukemia

A Review of the Genetic Variants Affecting Efficacy and Adverse Effects of Standard of Care Treatment in Patients with Chronic Myelogenous Leukemia

“…According to recent research, individuals with GSTP1 AA/AG genotypes alone and in conjunction with GSTT1 null genotypes acquire cytogenetic response of imatinib faster, however, patients with GSTP1-GG and GSTMI positive genotypes may take longer to achieve imatinib cytogenetic response. (Delmond et al 2021). A meta-analysis of CML patients showed that G allele carriers with GSTP1 Ile105Val polymorphism had significantly worse responses to imatinib treatment (Lee et al 2020).…”

Research Article <i>GSTM1</i>/<i>GSTT1</i>-null genotyping role in leukemia development in Brazilian patients

“…Acute myeloid leukemia is the most common malignant and aggressive leukemia in adults, being a disease caused by the uncontrolled growth of myeloid or lymphoid cells that lose the power of cell differentiation (Gregory et al, 2019). Chronic myeloid leukemia is given by a reciprocal translocation (9; 22) (q34; q11) that results in a Philadelphia chromosome (Ph+), by a fusion of ABL and BCR genes (Abelson's murine on chromosome 9 and Breakpoint cluster on chromosome 22) leading to an unbalanced proliferation of myeloid lineage cells (Delmond et al, 2021). Acute lymphoid leukemia is a type of leukemia that typically has a clone of immature B or T cells in the bone marrow causing problems with hematopoiesis.…”